Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Treasury Shares (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Treasury Shares for 7 consecutive years, with $194419.0 as the latest value for Q4 2025.

  • On a quarterly basis, Treasury Shares fell 89.36% to $194419.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $194419.0, a 89.36% decrease, with the full-year FY2025 number at $194419.0, down 89.36% from a year prior.
  • Treasury Shares was $194419.0 for Q4 2025 at Rhythm Pharmaceuticals, down from $1.8 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $1.8 million in Q4 2024 to a low of $194419.0 in Q4 2025.
  • A 5-year average of $762445.8 and a median of $581346.0 in 2023 define the central range for Treasury Shares.
  • Peak YoY movement for Treasury Shares: surged 214.22% in 2024, then plummeted 89.36% in 2025.
  • Rhythm Pharmaceuticals' Treasury Shares stood at $435589.0 in 2021, then surged by 77.73% to $774166.0 in 2022, then decreased by 24.91% to $581346.0 in 2023, then soared by 214.22% to $1.8 million in 2024, then tumbled by 89.36% to $194419.0 in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Treasury Shares are $194419.0 (Q4 2025), $1.8 million (Q4 2024), and $581346.0 (Q4 2023).